Literature DB >> 3777162

Glucose and fructose 6-phosphate cycle in humans.

S Karlander, A Roovete, M Vranić, S Efendić.   

Abstract

We have determined the rate of glucose cycling by comparing turnovers of [2-3H]- and [6-3H]glucose under basal conditions and during a glucose infusion. Moreover, the activity of the fructose 6-phosphate cycle was assessed by comparing [3-3H]- and [6-3H]glucose. The study included eight lean subjects with normal glucose tolerance. They participated in two randomly performed investigations. In one experiment [2-3H]- and [6-3H]glucose were given simultaneously, while in the other only [3-3H]glucose was given. The basal rate of glucose cycling was 0.32 +/- 0.08 mg X kg-1 X min-1 or 17% of basal glucose production (P less than 0.005). During glucose infusion the activity of endogenous glucose cycling did not change but since glucose production was suppressed it amounted to 130% of glucose production. The basal fructose 6-phosphate cycle could be detected only in three subjects and was suppressed during glucose infusion. In conclusion, the glucose cycle is active in healthy humans both in basal conditions and during moderate hyperglycemia. In some subjects, the fructose 6-phosphate cycle also appears to be active. Thus it is preferable to use [6-3H]glucose rather than [3-3H]glucose when measuring glucose production and particularly when assessing glucose cycle.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3777162     DOI: 10.1152/ajpendo.1986.251.5.E530

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  13 in total

1.  Nocturnal Glucose Metabolism in Type 1 Diabetes: A Study Comparing Single Versus Dual Tracer Approaches.

Authors:  Ashwini Mallad; Ling Hinshaw; Chiara Dalla Man; Claudio Cobelli; Rita Basu; Ravi Lingineni; Rickey E Carter; Yogish C Kudva; Ananda Basu
Journal:  Diabetes Technol Ther       Date:  2015-06-29       Impact factor: 6.118

2.  In vivo glucosamine infusion induces insulin resistance in normoglycemic but not in hyperglycemic conscious rats.

Authors:  L Rossetti; M Hawkins; W Chen; J Gindi; N Barzilai
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

3.  Multiple defects of both hepatic and peripheral intracellular glucose processing contribute to the hyperglycaemia of NIDDM.

Authors:  A Vaag; F Alford; F L Henriksen; M Christopher; H Beck-Nielsen
Journal:  Diabetologia       Date:  1995-03       Impact factor: 10.122

4.  Increased epinephrine and skeletal muscle responses to hypoglycemia in non-insulin-dependent diabetes mellitus.

Authors:  H Shamoon; S Friedman; C Canton; L Zacharowicz; M Hu; L Rossetti
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

5.  Mechanism by which hyperglycemia inhibits hepatic glucose production in conscious rats. Implications for the pathophysiology of fasting hyperglycemia in diabetes.

Authors:  L Rossetti; A Giaccari; N Barzilai; K Howard; G Sebel; M Hu
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

6.  Predominant role of gluconeogenesis in the hepatic glycogen repletion of diabetic rats.

Authors:  A Giaccari; L Rossetti
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

7.  Importance of glucagon in the control of futile cycling as studied in alloxan-diabetic dogs.

Authors:  H L Lickley; F W Kemmer; K M el-Tayeb; M Vranic
Journal:  Diabetologia       Date:  1987-03       Impact factor: 10.122

8.  Contribution of glucose/glucose 6-phosphate cycle activity to insulin resistance in type 2 (non-insulin-dependent) diabetes mellitus.

Authors:  D P Rooney; R D Neely; O Beatty; N P Bell; B Sheridan; A B Atkinson; E R Trimble; P M Bell
Journal:  Diabetologia       Date:  1993-02       Impact factor: 10.122

9.  Hormonal control of substrate cycling in humans.

Authors:  H Miyoshi; G I Shulman; E J Peters; M H Wolfe; D Elahi; R R Wolfe
Journal:  J Clin Invest       Date:  1988-05       Impact factor: 14.808

10.  Mild type II diabetes markedly increases glucose cycling in the postabsorptive state and during glucose infusion irrespective of obesity.

Authors:  S Efendic; S Karlander; M Vranic
Journal:  J Clin Invest       Date:  1988-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.